Search results for " type 2"

showing 10 items of 761 documents

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

2013

<b><i>Background:</i></b> Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. <b><i>Patients and Methods:</i></b> Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). <b><i>Results:<…

OncologyCancer Researchmedicine.medical_specialtyAnthracyclineSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentPopulationAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedVentricular Function LeftBreast cancer; Elderly patients; Human epidermal growth factor receptor type 2; TrastuzumabBreast cancerBreast cancerTrastuzumabInternal medicinemedicineHumansAdverse effecteducationGeriatric AssessmentAgedRetrospective StudiesAged 80 and overChemotherapyCardiotoxicityeducation.field_of_studybusiness.industryRetrospective cohort studyGeneral MedicineTrastuzumabmedicine.diseaseHuman epidermal growth factor receptor type 2OncologyFemalebusinessElderly patientmedicine.drugOncology
researchProduct

The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysi…

2014

Consumption of a Mediterranean diet (MD) and genetic variation in the glucokinase regulatory protein (GCKR) gene have been reported to be associated with TAG and glucose metabolism. It is uncertain whether there is any interaction between these factors. Therefore, the aims of the present study were to test the association of adherence to a MD and rs780094 (G>A) SNP in theGCKRgene with the markers of cardiometabolic risk, and to investigate the interaction between genetic variation and MD adherence. We studied 20 986 individuals from the European Prospective Investigation into Cancer (EPIC)-Norfolk study. The relative Mediterranean Diet Score (rMED: range 0–18) was used to assess MD adher…

OncologyMaleMediterranean dietMedicine (miscellaneous)030204 cardiovascular system & hematologyDiet MediterraneanCohort Studies0302 clinical medicineGenotype030212 general & internal medicineProspective StudiesGene–environment interactionProspective cohort studyNutrition and DieteticsGlucokinase regulatory proteinConfoundingDietary Surveys and Nutritional EpidemiologyMiddle AgedFull PapersLipids3. Good healthEnglandCardiovascular DiseasesFemaleAdultRiskmedicine.medical_specialtyBiologyPolymorphism Single Nucleotide03 medical and health sciencesInternal medicineMediterranean dietGenetic variationmedicineSNPHumansGenetic Association StudiesAdaptor Proteins Signal TransducingAgedGlycated HemoglobinCardiometabolic riskEndocrinologyCross-Sectional StudiesApolipoproteinsDiabetes Mellitus Type 2biology.proteinPatient ComplianceGene-Environment InteractionGlucokinase regulatory proteinBiomarkersThe British journal of nutrition
researchProduct

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

2021

Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical stud…

Oncologyendocrine system diseasesColorectal cancerComorbidityReview0302 clinical medicineinsulin resistanceEpidemiologyBiology (General)small dense LDLSpectroscopyglucagon-like peptide-1 receptor agonists0303 health sciencesIncidenceGeneral MedicineSmall dense LDL3. Good healthComputer Science ApplicationsLipoproteins LDLChemistry030220 oncology & carcinogenesismedicine.symptomColorectal Neoplasmsmedicine.medical_specialtyQH301-705.5InflammationCatalysisGlucagon-like peptide-1 receptor agonistsGlucagon-Like Peptide-1 ReceptorInorganic Chemistry03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIn patientPhysical and Theoretical ChemistryQD1-999Molecular BiologyAntidiabetic agents030304 developmental biologyInflammationbusiness.industryOrganic ChemistryType 2 Diabetes Mellitusnutritional and metabolic diseasesInsulin resistanceGlucagon-like peptide-1 receptor agonists Hyperglycemia Inflammation Insulin resistance Comorbidity Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hyperglycemia Hypoglycemic Agents Incidence Lipoproteins LDL Oxidative Stress Colorectal Neoplasms Small dense LDLmedicine.diseasedigestive system diseasesOxidative StressDiabetes Mellitus Type 2Oxidative stressinflammationHyperglycemiabusinessInternational journal of molecular sciences
researchProduct

Insulin withdrawal in diabetic kidney disease : What are we waiting for?

2021

The prevalence of type 2 diabetes mellitus worldwide stands at nearly 9.3% and it is estimated that 20–40% of these patients will develop diabetic kidney disease (DKD). DKD is the leading cause of chronic kidney disease (CKD), and these patients often present high morbidity and mortality rates, particularly in those patients with poorly controlled risk factors. Furthermore, many are overweight or obese, due primarily to insulin compensation resulting from insulin resistance. In the last decade, treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be beneficial in renal and cardiovascular targets; however…

Opinionmedicine.medical_specialtyinsulinHealth Toxicology and Mutagenesismedicine.medical_treatmentRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologyOverweight03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseInternal medicinemedicineHumansHypoglycemic AgentsInsulinDiabetic NephropathiesSGLT2iDiabetic kidney diseaseSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetisbusiness.industryInsulinMortality ratePublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseRepaglinideCardiovascular diseaseGLP-1RAdiabetic kidney diseaseCor MalaltiesDiabetes Mellitus Type 2Medicinemedicine.symptombusinessKidney diseasemedicine.drug
researchProduct

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.

2019

BACKGROUND Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. METHODS We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular risk (age of ≥50 years with established cardiovascular or chronic kidney disease, or age of ≥60 years with cardiovascular risk factors only). The primary outcome in a time-to-event analysis was the first occurrence of a major adverse cardiovascular event (death fro…

OralMaleRiskGlucagon-Like PeptideGlycated Hemoglobin AGlucagon-Like PeptidesAdministration OralGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodCardiovascular DiseaseDiabetes MellitusHumansHypoglycemic AgentsSettore MED/49 - Scienze Tecniche Dietetiche ApplicateAgedGlycated HemoglobinHypoglycemic AgentMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]General MedicineMiddle AgedAdministration Oral; Aged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Male; Middle Aged; RiskDiabetes Mellitus Type 2Cardiovascular DiseasesAdministrationFemaleType 2Human
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

MALIGNANT TUMOR-LIKE GAASTRIC LESION DUE TO CANDIDA ALBICANS IN A DIABETIC PATIENT TREATED WITH CYCLOSPORIN: A CASE REPORT AND REVIEW OF THE LITERATU…

2012

The gastrointestinal tract of healthy individuals is colonized by hundreds of saprophytes and mycetes, especially the Candida species, are habitual ones. Under certain conditions, the fungal flora may overgrow, resulting in lesions of the digestive mucosa which, rarely, can have a local diffusion and/or spread to the lympho-hematogenous system. Mycotic infections of the stomach can sometimes look like benign gastric ulcers. Here, we present the case report of a woman, aged 64, who presented with type II diabetes mellitus and psoriasis, on chronic treatment with cyclosporin A and with endoscopic evidence of an ulcerated, vegetating gastric lesion secondary to Candida albicans infection. Alth…

Pathologymedicine.medical_specialtyAntifungal AgentsSettore MED/09 - Medicina InternaSettore MED/08 - Anatomia PatologicaMalignancyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyCyclosporin aDiabetes mellitusInternal medicinePsoriasisCandida albicansCandidiasis Mycotic infection of the gastrointestinal tract submucosal tumorHumansMedicineStomach UlcerCandida albicansGastrointestinal tractHematologybiologybusiness.industryStomachCandidiasisGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureDiabetes Mellitus Type 2CyclosporineFemaleItraconazolebusiness
researchProduct

Renal papillary necrosis, an endoscopic vision.

2019

Renal papillary necrosis is described as an ischemic or chemical lesion at the end of the Malpighi pyramid, which causes the necrosis, with detachment and expulsion of the papilla in the urine. It ...

Pathologymedicine.medical_specialtyNecrosisUrology030232 urology & nephrologyHydronephrosis030204 cardiovascular system & hematologyRenal papillary necrosisLesion03 medical and health sciences0302 clinical medicinestomatognathic systemX ray computedUreteroscopyMedicineHumansDiabetic Nephropathiesintegumentary systemurogenital systembusiness.industryfood and beveragesUrographyMiddle Agedmedicine.diseaseMajor duodenal papillaDiabetes Mellitus Type 2NephrologyFemaleKidney Papillary Necrosismedicine.symptombusinessTomography X-Ray ComputedPyelogramScandinavian journal of urology
researchProduct

Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions

2013

Maliszewska, Agnieszka et al.

Pathologymedicine.medical_specialtyendocrine system diseasesInheritance PatternsMultiple endocrine neoplasia type 2ApoptosisBiologyGermlinePathology and Forensic MedicineThyroid carcinomaAntigens CDCell Line TumormedicineBiomarkers TumorGene silencingCluster AnalysisHumansGenetic Predisposition to DiseaseAC133 AntigenGene SilencingThyroid NeoplasmsRNA Small InterferingGlycoproteinsRegulation of gene expressionTissue microarrayReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingWnt signaling pathwaymedicine.diseaseImmunohistochemistryCarcinoma NeuroendocrineGene expression profilingGene Expression Regulation NeoplasticGene Knockdown TechniquesCancer researchPeptides
researchProduct

Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients withCLN2 mutations

2002

We examined 26 individuals with clinical and electron microscopic signs of late infantile neuronal ceroid lipofuscinosis (LINCL). In 22 cases, we found both pathogenic alleles. Sixteen patients exclusively carried either one or a combination of the two common mutations R208X and IVS5-1G > C. In the remaining cases, four missense mutations could be detected, of which R127Q, N286S, and T353P represent novel, previously not described alleles. A clinical performance score was developed by rating motor, visual, and verbal functions and the incidence of cerebral seizures in 3-month intervals during the course of the disease. A Total Disability Score was derived by summing up the single scores for…

Pediatricsmedicine.medical_specialtyDNA Mutational AnalysisCerliponase alfaDiseaseNeurological disorderAminopeptidasesSeverity of Illness IndexNeuronal Ceroid-LipofuscinosesSeizuresEndopeptidasesSeverity of illnessmedicineMissense mutationDipeptidyl-Peptidases and Tripeptidyl-PeptidasesVision OcularGenetics (clinical)Tripeptidyl-Peptidase 1business.industryDNAmedicine.diseaseTripeptidyl peptidase INeuronal Ceroid Lipofuscinosis Type 2MutationNeuronal ceroid lipofuscinosisSerine ProteasesbusinessPsychomotor PerformancePeptide HydrolasesAmerican Journal of Medical Genetics
researchProduct